Outlook Therapeutics (OTLK) Competitors $1.70 -0.06 (-3.41%) As of 05/20/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OTLK vs. ANNX, NVCT, AARD, AMRN, MNPR, DRUG, SLRN, OCGN, SLDB, and BTMDShould you be buying Outlook Therapeutics stock or one of its competitors? The main competitors of Outlook Therapeutics include Annexon (ANNX), Nuvectis Pharma (NVCT), Aardvark Therapeutics (AARD), Amarin (AMRN), Monopar Therapeutics (MNPR), Bright Minds Biosciences (DRUG), Acelyrin (SLRN), Ocugen (OCGN), Solid Biosciences (SLDB), and biote (BTMD). These companies are all part of the "pharmaceutical products" industry. Outlook Therapeutics vs. Annexon Nuvectis Pharma Aardvark Therapeutics Amarin Monopar Therapeutics Bright Minds Biosciences Acelyrin Ocugen Solid Biosciences biote Annexon (NASDAQ:ANNX) and Outlook Therapeutics (NASDAQ:OTLK) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, community ranking, earnings, dividends, media sentiment, valuation, profitability and institutional ownership. Which has preferable valuation and earnings, ANNX or OTLK? Outlook Therapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnnexonN/AN/A-$134.24M-$1.18-1.78Outlook TherapeuticsN/AN/A-$75.37M-$0.91-1.87 Which has more risk & volatility, ANNX or OTLK? Annexon has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Outlook Therapeutics has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500. Does the media refer more to ANNX or OTLK? In the previous week, Annexon had 17 more articles in the media than Outlook Therapeutics. MarketBeat recorded 21 mentions for Annexon and 4 mentions for Outlook Therapeutics. Outlook Therapeutics' average media sentiment score of 0.76 beat Annexon's score of 0.32 indicating that Outlook Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 4 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Outlook Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate ANNX or OTLK? Annexon presently has a consensus target price of $12.50, indicating a potential upside of 495.24%. Outlook Therapeutics has a consensus target price of $10.20, indicating a potential upside of 500.00%. Given Outlook Therapeutics' higher probable upside, analysts plainly believe Outlook Therapeutics is more favorable than Annexon.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annexon 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Outlook Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Is ANNX or OTLK more profitable? Outlook Therapeutics' return on equity of 0.00% beat Annexon's return on equity.Company Net Margins Return on Equity Return on Assets AnnexonN/A -38.99% -33.90% Outlook Therapeutics N/A N/A -225.12% Does the MarketBeat Community prefer ANNX or OTLK? Outlook Therapeutics received 108 more outperform votes than Annexon when rated by MarketBeat users. However, 78.08% of users gave Annexon an outperform vote while only 71.12% of users gave Outlook Therapeutics an outperform vote. CompanyUnderperformOutperformAnnexonOutperform Votes5778.08% Underperform Votes1621.92% Outlook TherapeuticsOutperform Votes16571.12% Underperform Votes6728.88% Do insiders and institutionals have more ownership in ANNX or OTLK? 11.2% of Outlook Therapeutics shares are held by institutional investors. 11.9% of Annexon shares are held by insiders. Comparatively, 4.8% of Outlook Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryOutlook Therapeutics beats Annexon on 9 of the 15 factors compared between the two stocks. Get Outlook Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OTLK vs. The Competition Export to ExcelMetricOutlook TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$55.45M$2.97B$5.42B$8.48BDividend YieldN/A1.72%5.22%4.11%P/E Ratio-0.2331.5826.8320.05Price / SalesN/A429.82393.90117.05Price / CashN/A168.6838.2534.62Price / Book-1.083.376.874.61Net Income-$75.37M-$72.17M$3.22B$248.19M7 Day Performance-2.86%18.10%6.76%2.97%1 Month Performance15.65%20.85%13.66%16.58%1 Year Performance-78.40%-24.45%18.27%8.16% Outlook Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OTLKOutlook Therapeutics2.039 of 5 stars$1.70-3.4%$10.20+500.0%-78.6%$55.45MN/A-0.2320Earnings ReportUpcoming EarningsANNXAnnexon1.8758 of 5 stars$2.09+4.0%$12.50+498.1%-55.1%$229.30MN/A-1.9960Gap DownNVCTNuvectis Pharma3.0547 of 5 stars$10.95+10.9%$17.00+55.3%+78.1%$228.79MN/A-9.448Positive NewsAARDAardvark TherapeuticsN/A$10.43+5.5%$31.25+199.6%N/A$226.29MN/A0.0018News CoverageEarnings ReportAnalyst RevisionAMRNAmarin0.3595 of 5 stars$10.90+3.0%$7.00-35.8%-36.9%$225.73M$214.11M-121.11360MNPRMonopar Therapeutics2.94 of 5 stars$36.90-0.7%$55.33+50.0%+1,090.5%$225.64MN/A-18.7310DRUGBright Minds Biosciences3.7921 of 5 stars$31.99-3.1%$83.25+160.2%+2,878.0%$225.34MN/A-188.17N/APositive NewsEarnings ReportUpcoming EarningsSLRNAcelyrin3.6268 of 5 stars$2.23-0.9%$9.60+330.5%-47.2%$225.13MN/A-0.91135Positive NewsEarnings ReportOCGNOcugen1.1778 of 5 stars$0.77+1.5%$6.00+679.4%-57.8%$224.81M$4.52M-4.2880Gap DownSLDBSolid Biosciences4.3317 of 5 stars$2.90+4.7%$14.78+409.6%-67.7%$224.76M$8.09M-0.95100Earnings ReportAnalyst ForecastAnalyst RevisionBTMDbiote2.9219 of 5 stars$4.06-1.0%$8.00+97.0%-29.4%$222.12M$199.38M15.62194Gap Up Related Companies and Tools Related Companies Annexon Competitors Nuvectis Pharma Competitors Aardvark Therapeutics Competitors Amarin Competitors Monopar Therapeutics Competitors Bright Minds Biosciences Competitors Acelyrin Competitors Ocugen Competitors Solid Biosciences Competitors biote Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OTLK) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Outlook Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Outlook Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OTLK Stock Free OTLK Stock Alerts